Although recent studies showed improved outcomes with the use of decitabine in TP53 mutated AML and higher-risk MDS, responses are usually short-lasting and even patients achieving a morphological CR had next-generation sequencing (NGS) minimally residual disease (MRD) detectable clone(s) which later on were attributable to patients’ relapse [34]. Here, TP53 is linked to acute myeloid leukemia.